Close

BIO Submits Comments Re: HHS Notice of Benefit and Payment Parameters for 2017

Dec 22 2015
Sylvia Mathews Burwell Secretary U.S. Department of Health and Human Services 200 Independence Avenue, S.W. Washington, D.C. 20201   Andrew M. Slavitt Acting Administrator Centers for Medicare and Medicaid Services 7500 Security Boulevard Baltimore, M.D. 21244   BY ELECTRONIC DELIVERY   Re: Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2017 [CMS-9937-P]  

BIO Submits Comments Re: Methods for Assuring Access to Covered Medicaid Services Final Rule with Comment

Dec 22 2015
Andrew Slavitt Acting Administrator Centers for Medicare & Medicaid Services Department of Health and Human Services Hubert H. Humphrey Building, Room 445-G 200 Independence Avenue, SW Washington, DC 20201   Re: Medicaid Program; Methods for Assuring Access to Covered Medicaid Services; Final Rule with Comment [CMS-2328-FC]   Dear Acting Administrator Slavitt:   The Biotechnology Industry Organization (BIO) is pleased to submit comments on the Centers for Medicare and Medicaid Services’ (CMS’s) final rule with comment entitled Medicaid Program; Methods for Ensuring Access to Covered Medicaid Services; Final Rule with Comment (the "FC"). 

BIO Submits Comments Re: Data Metrics and Alternative Processes for Access to Care in the Medicaid Program RFI

Dec 22 2015
Andrew Slavitt Acting Administrator Centers for Medicare & Medicaid Services Department of Health and Human Services Hubert H. Humphrey Building, Room 445-G 200 Independence Avenue, SW Washington, DC 20201   RE: Data Metrics and Alternative Processes for Access to Care in the Medicaid Program Request for Information [CMS-2328-NC]   Dear Acting Administrator Slavitt: The Biotechnology Industry Organization (BIO) is pleased to submit comments on the Centers for Medicare and Medicaid Services’ (CMS’s) Request for Information entitled Medicaid Program; Request for Information (RFI) – Data Metrics and Alternative Processes for Access to Care in the Medicaid Program (the "RFI"). 

BIO Submits Comments Re: Medicare Shared Savings Program: Accountable Care Organizations Proposed Rule

Dec 22 2015
Marilyn Tavenner Administrator Centers for Medicare & Medicaid Services Department of Health and Human Services Room 445-G Hubert H. Humphrey Building 200 Independence Avenue, S.W. Washington, D.C. 20201   Re: Medicare Program; Medicare Shared Savings Program: Accountable Care Organizations   Dear Administrator Tavenner:   The Biotechnology Industry Organization (BIO) appreciates this opportunity to comment on the Centers for Medicare & Medicaid Services’ (CMS) proposed rule regarding the Medicare Shared Savings Program (MSSP) and Accountable Care Organizations (ACOs) (the “Proposed Rule”).1 BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of health care, agricultural, industrial, and environmental biotechnology products.

BIO Submits Comments Re: MA Capitation Rates, Part C and Part D Payment Policies and 2016 Draft Call Letter

Dec 22 2015
Sean Cavanaugh Deputy Administrator Director, Center for Medicare Centers for Medicare & Medicaid Services 7500 Security Boulevard Baltimore, MD 21244 cc: Jennifer Wuggazer Lazio, F.S.A., M.A.A.A. Director Parts C & D Actuarial Group Office of the Actuary Re: Advance Notice of Methodological Changes for Calendar Year (CY) 2016 for Medicare Advantage (MA) Capitation Rates, Part C and Part D Payment Policies and 2016 Call Letter (“draft 2016 Call Letter”) Dear Mr. Cavanaugh: The Biotechnology Industry Organization (BIO) appreciates this opportunity to comment on the Centers for Medicare and Medicaid Services’ (CMS’s) draft 2016 Call Letter. BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO's members develop medical products and technologies to treat patients afflicted with serious diseases, to delay the onset of these diseases, or to prevent them in the first place. In that way, our members’ novel therapeutics, vaccines, and diagnostics not only have improved health outcomes, including productivity and quality of life, but also have reduced healthcare expenditures due to fewer physician office visits, hospitalizations, and surgical interventions.  

BIO Submits Comments Re: MIPS, Promotion of Alternative Payment Models, and Incentive Payments for Participation in Eligible Alternative Payment Models RFI

Dec 22 2015
Andy Slavitt Acting Administrator Centers for Medicare and Medicaid Services 7500 Security Boulevard Baltimore, M.D. 22224 BY ELECTRONIC DELIVERY RE: CMS Regarding Implementation of the Merit-Based Incentive Payment System, Promotion of Alternative Payment Models, and Incentive Payments for Participation in Eligible Alternative Payment Models Dear Acting Administrator Slavitt: The Biotechnology Industry Organization is pleased to submit feedback in response to the Centers for Medicare and Medicaid Services’ (CMS’s) Request for Information entitled “CMS Regarding Implementation of the Merit-Based Incentive Payment System (MIPS), Promotion of Alternative Payment Models, and Incentive Payments for Participation in Eligible Alternative Payment Models,” (the “RFI”) released October 1, 2015.

BIO Submits Comments Re: 2017 Star Ratings Update

Dec 22 2015
BIO Draft Comments in Response to the 2017 Star Ratings Update Request for Comments Note to Members: CMS requires that responses to individual proposed updates be submitted through an online form individually. Given these formatting requirements, BIO’s draft comments will not follow our traditional comment letter format.  

BIO Submits Comments Re: Medicare Inpatient Prospective Payment System (IPPS) Proposed Rule

Dec 22 2015
Re: Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective payment System Policy Changes and Fiscal Year 2016 Rates; Revisions of Quality Reporting Requirements for Specific Providers, Including Changes Related to the Electronic Health Record Incentive Program; Proposed Rule Dear Acting Administrator Slavitt: The Biotechnology Industry Organization (BIO) appreciates this opportunity to comment on the Centers for Medicare and Medicaid Services’ (CMS’s) Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Proposed Fiscal Year 2016 Rates Proposed Rule (the “Proposed Rule”), including with respect to the Hospital Inpatient Quality Reporting (IQR) Program and the Hospital Value-Based Purchasing (VBP) Program. BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial, and environmental biotechnology products. 

BIO Submits Comments Re: Nondiscrimination in Health Programs and Activities

Dec 17 2015
The Biotechnology Industry Organization (BIO) is pleased to submit the following comments in response to the Department of Health and Human Services’ (HHS’s) Proposed Rule entitled “Nondiscrimination in Health Programs and Activities” published on September 8, 2015 (the “Proposed Rule”).1 BIO represents biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and in more than 30 other nations. BIO’s members develop medical products and technologies to treat patients afflicted with serious diseases, to delay the onset of these diseases, or to prevent them in the first place. In that way, our members’ novel therapeutics, vaccines, and diagnostics not only have improved health outcomes, but also have reduced healthcare expenditures due to fewer physician office visits, hospitalizations, and surgical interventions.

BIO Comments on Draft Patents (Amendment) Rule 2015

Dec 15 2015
The Biotechnology Industry Organization (BIO) greatly appreciates the opportunity to provide comments/suggestions of the stakeholders on the Draft Patents (Amendment) Rules 2015 published by the Ministry of Commerce & Industry.